Introduction
The rapid growth of GLP-1 receptor agonists such as semaglutide, liraglutide, dulaglutide, and emerging dual/triple agonists in treating type-II diabetes has increased the importance of robust bioanalytical strategies to ensure product quality, potency, safety, and efficacy. As the industry scales manufacturing capacity globally, bioassay-based batch release testing has become a critical component of the control strategy for APIs, finished products, and prefilled syringe presentations.
Unlike conventional small molecules, GLP-1 agonists require demonstration of biological activity in addition to physicochemical characterisation. Regulatory expectations emphasise validated analytical procedures and potency assays that are scientifically justified, accurate, reproducible, and suitable for their intended use.
Why bioassays matter for GLP-1 agonists
A bioassay measures the functional activity of a drug substance/product against its biological target. For GLP-1 receptor agonists, potency is typically evaluated through receptor activation assays that measure downstream signalling pathways such as cAMP generation, CRE-luciferase reporter activity, or other mechanism-of-action relevant cellular responses.
These assays provide direct evidence that the molecule retains its expected biological function throughout:
- API release
- Drug product formulation
- Storage and stability lifecycle
- Commercial batch release testing
Batch release testing across the product lifecycle
API testing
For GLP-1 APIs, quality control typically includes:
- Identity confirmation
- Purity and impurity profiling
- Peptide content assay
- Related substances
- Biological potency evaluation
The potency assay confirms that the active peptide maintains its receptor-binding and signaling capability after synthesis, purification, and storage.
Finished product testing
Finished dosage forms require additional assessment because formulation components can potentially impact biological activity. Typical release tests include:
- Potency/Bioactivity
- Assay and content uniformity
- Aggregation profile
- Degradation products
- pH and appearance
- Sterility and endotoxin testing
A validated bioassay provides assurance that formulation processes have not altered the molecule’s biological performance.
Prefilled syringe testing
Prefilled syringe presentations introduce additional variables:
- Siliconisation effects
- Container closure interactions
- Adsorption to contact surfaces
- Mechanical stress during filling
Consequently, potency monitoring becomes particularly important to demonstrate that biological activity remains unchanged from bulk drug product through final container closure systems.
Method development strategy
Successful bioassay development begins with a clear understanding of the molecule’s mechanism of action. For GLP-1 agonists, commonly employed platforms include:
cAMP functional assays
Measure intracellular cAMP accumulation following GLP-1 receptor activation.
Advantages:
- Direct MOA relevance
- High sensitivity
- Well-established platform
Reporter gene assays
CRE-Luciferase systems convert receptor activation into a quantifiable luminescent signal.
Advantages:
- Excellent throughput
- Robust response window
- Suitability for QC environments
Receptor activation assays
These cell-based assays directly evaluate functional receptor engagement and downstream signaling.
Critical development considerations
- Cell line selection
- Reference standard qualification
- Dynamic assay range
- Signal-to-noise ratio
- Data fitting model
- Assay robustness and transferability
Learn more about our in vitro and in vivo pharmacology solutions supporting cell-based development programmes.
Method validation: key regulatory expectations
According to ICH Q2(R2) and USP <1033>, bioassays used for release testing must be validated to demonstrate fitness for purpose. The key validation parameters are listed below.
Accuracy
Accuracy demonstrates agreement between measured and expected potency values. For GLP-1 bioassays, accuracy is commonly evaluated through:
- Recovery studies
- Relative potency samples
- Spiked preparations
Acceptance criteria are established based on intended assay use and manufacturing variability.
Precision
Precision measures closeness between independent test results.
Repeatability (Intra-assay precision)
Evaluates variability within a single run. Typical factors:
- Same analyst
- Same equipment
- Same day
- Multiple replicates
Intermediate precision
Evaluates:
- Different analysts
- Different days
- Different reagent lots
- Different instruments
Reproducibility
Measures performance across laboratories and during method transfer activities. For global GLP-1 manufacturing networks, reproducibility is often a key indicator of assay readiness for commercial implementation.
Linearity
Linearity demonstrates that assay response remains proportional to concentration across the intended operating range. For GLP-1 potency assays, evaluation typically includes:
- 50% to 150% relative potency range
- Multiple concentration levels
- Dose-response modeling
Results should show consistent relative potency estimation throughout the validated range.
Range
The validated range represents concentrations over which acceptable:
- Accuracy
- Precision
- Linearity
have been demonstrated. An appropriately defined range minimises out-of-specification investigations and supports routine QC operations.
Specificity
Specificity confirms that the assay measures the intended biological activity and is not influenced by:
- Excipients
- Degradation products
- Process impurities
- Matrix effects
This is particularly important for finished product and prefilled syringe testing.
Robustness
Robustness studies demonstrate assay reliability under small deliberate variations such as:
- Incubation time
- Cell density
- Reagent lot changes
- Temperature variations
Robust methods significantly reduce analytical risk during commercial manufacturing.
Our bioanalytical services team supports assay development, validation and method transfer across development programmes.
Dose formulation analysis
Dose formulation analysis ensures the administered dose accurately reflects the labelled claim and intended biological activity. For GLP-1 products, dose formulation assessments typically include:
- Concentration verification
- Potency confirmation
- Homogeneity evaluation
- Stability assessment during use
These studies are especially important during development, clinical manufacturing, and comparability exercises following process changes.
Explore how our DMPK studies support compound characterisation and development decisions.
The future of GLP-1 bioassay testing
As the market expands beyond semaglutide into dual and triple agonist platforms in type-II diabetes treatment, analytical strategies must evolve to support increasingly complex mechanisms of action. Advanced cell-based assays, digital data analytics, lifecycle validation approaches, and globally harmonised potency standards are expected to become central pillars of next-generation batch release programs.
Learn how we support pharmaceutical and biotechnology programmes, from IND-enabling studies to NDA filing.
Why partner with Adgyl Lifesciences?
With experience & expertise Adgyl supports bioassays across diverse therapeutic areas, including GLP-1 agonists. Our key capabilities include:
GLP-1 agonist-specific capabilities
- End-to-end bioassay support – Capability to support GLP-1 agonist programs from API/drug substance through formulated drug product and prefilled syringe, enabling consistent potency assessment across the product lifecycle.
- Relevant cell-based potency platforms – Experience in developing and executing mechanism-of-action-aligned functional bioassays, including receptor-mediated signaling and downstream response assays relevant to GLP-1 agonists.
Bioassay support across therapeutic areas
- Method development to routine batch release – Integrated support covering assay development, optimisation, qualification/validation, method transfer, and routine GMP batch-release testing.
- GLP & GMP testing infrastructure – Quality systems and laboratory infrastructure supporting regulated bioanalytical testing, with an emphasis on data integrity, traceability, controlled documentation, and reproducibility.
- API-to-drug-product comparability – Bioassay strategies designed to demonstrate consistent biological activity across API, formulated product, and device-presented product, helping identify potential impacts of formulation, manufacturing, or presentation.
- Lifecycle and stability support – Potency testing to support release, stability programs, formulation/process changes, investigations, and comparability exercises.
- Fit-for-purpose assay strategy – Assays tailored around the molecule’s mechanism of action, intended product stage, specifications, and regulatory objective, rather than a one-size-fits-all testing approach.
- Strong scientific and regulatory focus – Experienced scientific teams supporting assay troubleshooting, investigation of atypical/OOS results, method robustness, and regulatory-facing documentation.
Explore our bioanalytical services to learn more about the support available for your GLP-1 programme.
References
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2023). Validation of analytical procedures Q2(R2) (ICH Harmonised Guideline).
- United States Pharmacopeia. (2026). General chapter <1032> design and development of biological assays. In USP–NF. uspnf.com
- United States Pharmacopeia. (2026). General chapter <1033> biological assay validation. In USP–NF. uspnf.com
- United States Pharmacopeia. (2026). General chapter <1034> analysis of biological assays. In USP–NF. uspnf.com